ArticleInfluenza and other respiratory viruses2023
Bacterial and viral infections among adults hospitalized with COVID-19, COVID-NET, 14 states, March 2020-April 2022.
Article in Influenza and other respiratory viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Convalescent plasma therapy for COVID-19 prophylaxis in adults early post-hematopoietic stem cell transplantation: one-year outcomes from a randomized controlled trial.Frontiers in immunology · 2025Trial
- Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).Microbiology spectrum · 2024Trial
- Risk Factors of Secondary Bacterial Infection in Patients Hospitalized with COVID-19.Journal of clinical medicine · 2026Article
- Antibiotic Prescribing in Patients Presenting with COVID-19: A Closed-Loop Audit with a Targeted Educational Intervention in a South Australian Hospital.Journal of clinical medicine · 2025Article
- On the Cause and Consequences of Coinfection: A General Mechanistic Framework of Within-Host Parasite Competition.Ecology letters · 2025Review
- Hidden in plain sight: the impact of human rhinovirus infection in adults.Respiratory research · 2025Review
- Unveiling the impact: COVID-19's influence on bacterial resistance in the Kingdom of Bahrain.World journal of virology · 2025Article
- Molecular characterization of human respiratory syncytial virus strains circulating among hospitalized children in Jordan.BMC infectious diseases · 2024Article
- Evaluation of an Affinity-Enhanced Anti-SARS-CoV2 Nanobody Design Workflow Using Machine Learning and Molecular Dynamics.Journal of chemical information and modeling · 2024Article
- Acute neutrophilic vasculitis (leukocytoclasia) in 36 COVID-19 autopsy brains.Diagnostic pathology · 2024Article
- Article
- Mortality in hospitalized SARS-CoV-2 patients with contemporaneous bacterial and fungal infections.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- [Bacterial coinfection in the critically-ill COVID-19 patient: incidence, impact and need for antimicrobial therapy].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Article
- Respiratory Coinfections in Children With SARS-CoV-2.The Pediatric infectious disease journal · 2023Article
- Inhalation phage therapy as a new approach to preventing secondary bacterial pneumonia in patients with moderate to severe COVID-19: A double-blind clinical trial study.Journal of drug delivery science and technology · 2023Article
- Bacterial and viral infections among adults hospitalized with COVID-19, COVID-NET, 14 states, March 2020-April 2022.Influenza and other respiratory viruses · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bacterial and viral infections can occur with SARS-CoV-2 infection, but prevalence, risk factors, and associated clinical outcomes are not fully understood. Methods: We used the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET), a population-based surveillance system, to investigate the occurrence of bacterial and viral infections among hospitalized adults with laboratory-confirmed SARS-CoV-2 infection between March 2020 and April 2022. Clinician-driven testing for bacterial pathogens from sputum, deep respiratory, and sterile sites were included. The demographic and clinical features of those with and without bacterial infections were compared. We also describe the prevalence of viral pathogens including respiratory syncytial virus, rhinovirus/enterovirus, influenza, adenovirus, human metapneumovirus, parainfluenza viruses, and non-SARS-CoV-2 endemic coronaviruses. Results: Among 36 490 hospitalized adults with COVID-19, 53.3% had bacterial cultures taken within 7 days of admission and 6.0% of these had a clinically relevant bacterial pathogen. After adjustment for demographic factors and co-morbidities, bacterial infections in patients with COVID-19 within 7 days of admission were associated with an adjusted relative risk of death 2.3 times that of patients with negative bacterial testing. Conclusions: Among patients with clinician-driven testing, 6.0% of adults hospitalized with COVID-19 were identified to have bacterial coinfections and 0.9% were identified to have viral coinfections; identification of a bacterial coinfection within 7 days of admission was associated with increased mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.